Key contacts

Peter Molloy

Peter Molloy
Founding Director

Simon Bindloss

Simon Bindloss
Business Development Manager

Regional office - North America
295 Madison Avenue
18th Floor, New York
NY10017 United States

Tel: +1 646 653 7026
enquires@edisongroup.com

listed companies

TransAtlantic Petroleum Afferro Mining
South American Silver Corp Infinity Pharmaceuticals
Exelixis Idenix
Pharmacyclics Ariad Pharmaceuticals
Arrowhead Research Corporation AVEO Pharmaceuticals
Sangamo BioSciences TransDigm Group
Array BioPharma Alnylam Pharmaceuticals
Spirit AeroSystems FLIR Systems
BioCryst Pharmaceuticals BioLineRx
Sucampo Pharmaceuticals Anthera Pharmaceuticals
See more

Companies with HQs in usa

Veris Gold Corp Nordgold
Ardea Biosciences CAE
Woulfe Mining RGI International
Altius Minerals Orbite Aluminae
Pan American Goldfields Nordion
Paladin Labs Dalradian Resources
Patheon Exact Sciences
MethylGene OPMEDIC Group
Torex Gold Canada Lithium Corporation
Xplore Technologies Corp Edgewater Exploration
See more

Latest research

Tonix Pharmaceuticals

Termination of coverage

Update | Pharmaceutical & healthcare | 22/06/2017

Edison Investment Research is terminating coverage on Tonix Pharmaceuticals (TNXP). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Orexigen Therapeutics

Contrave continues rebound

Outlook | Pharmaceutical & healthcare | 16/06/2017

Orexigen’s consumer-focused re-launch of Contrave continues to be successful with a 39% increase in prescriptions in the United States in Q117 compared to Q416. Outside of the US, progress continues as the product has launched in 14 countries, with another seven expected by the end of the year, including the Nordic countries, where Orexigen has just signed a local commercial and distribution partner.

Atossa Genetics

Funded into Q417, endoxifen now in Phase I

Update | Pharmaceutical & healthcare | 30/05/2017

Atossa raised $4.4m in April 2017 in an equity raise consisting of common shares, Series A convertible preferred shares (SACPS), and warrants. We believe the proceeds should extend its cash runway into Q417 as it advances its 30-patient Phase II study on IDMC-delivering fulvestrant in patients scheduled for mastectomy or lumpectomy, and its 48-patient Phase I trial on endoxifen. We obtain an rNPV-based equity valuation of $9.3m.

OTC Markets Group

Acceleration in corporate client signings

Outlook | Financials | 26/05/2017

OTC Markets Group’s (OTCM) first quarter results showed progress with revenues up 5% and pre-tax profits 12% ahead of Q116. While the corporate client count was down, there are encouraging signs of an improvement in the rate of new additions. OTCM continues to refine the rules for its premium markets to enhance their reputation while minimising the burden on corporates. The drive to increase the number of states that grant OTCM markets Blue Sky recognition continues as a further means to increase…

Track Group

Termination of coverage

Update | Technology | 24/05/2017

Edison Investment Research is terminating coverage on Track Group (TRCK). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Edison North America

Edison’s North American office opened in 2011 to provide research services to companies listed on North American stock exchanges. Companies of all sizes benefit from our research service, which provides the highest standards of equity research and unrivalled distribution of our reports on a global and unrestricted basis.